Deliver Your News to the World

co.don® AG –successful arthroscopic treatment of ankle with autologous 3-dimensional cultured chondrocytes - co.don chondrosphere® (ACT 3D)


August 1st, 2006 - German Biopharmaceutical company, co.don® AG (WKN: 517360) enhances the application spectrum of its product portfolio with the arthroscopic application of autologous 3-dimensional cultured cartilage -codon chondrosphere- (ACT -3D) for the arthroscopic treatment of chondrocyte defects in ankle.

On June 27, 2006, Dr. Lüthi, orthopaedic surgeon, SportClinic Zürich, Klinik Hirslanden, Schwitzerland, has successfully treated a cartilage defect in the ankle with co.don chondrosphere® under arthroscopic conditions. At the same time Dr. Baum, orthopaedic surgeon and head of Gelenkklinik Dr. Baum, Gundelfingen, Germany, was performing arthroscopic treatment of ankle using co.don chondrosphere® in Germany.

After first time worldwide successful treatment of comprehensive knee cartilage defects with chondrospheres by use of minimally invasive surgery – arthroscopy by Chiefsurgeon Dr. Dario Quattrocchi, in June, 26, 2005 (see press release June 26, 2005), co.don significant enhances its product and treatment portfolio. With co.don chondrosphere® it’s possible now to treat defects in smaller joints like the ankle.

The arthroscopy considerably reduces hospital days and duration of rehabilitation. This has an obvious impact on healthcare costs and as well, on patient’s recovery. co.don® ensures a sustainable competitive product advantage with their new product – co.don chondrosphere®. In Germany it is marked under the brand “ARTHROcell 3D” by ORMED GmbH & Co KG. In the Switzerland Market co.dons products are marked by CURMED AG.

co.don® is the European leader in the development and application of strictly autologous cell-based therapeutics for the regenerative treatment of lost or damaged tissues such as articular cartilage, intervertebral disc and bone.

In Germany approx. 10,000 ankle fractures are announced each year to the Employer’s Liability Insurance Association.

Management co.don AG

co.don® AG is one of the leading biopharmaceutical companies in the area of Regenerative Medicine/Tissue Engineering. Since 1997, co.don® AG develops, manufactures and distributes human Tissue engineering therapeutics for the regeneration of articular cartilage, bone and intervertebral discs.
The company is headquartered in Teltow near Berlin, Germany. For more information, please visit


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.